Infertility knows no bounds. But with the right team of global experts in the field, the safest and most innovative solutions, and a commitment to success, you have reason for hope.
IVI-RMA Global – which was born from the merger of Spain’s IVI and New Jersey’s Reproductive Medicine Associates of New Jersey in April 2017 – is the undisputed leader in infertility care.
As one unified global entity, IVI-RMA Global’s commitment to offering evidence-based fertility solutions is unparalleled. We provide hopeful parents the greatest chance of success in the shortest time possible. With more than 500 physicians and scientists in 88 fertility centers across 13 countries, IVI-RMA Global is literally changing the field of infertility.
If we see a problem that needs fixing, we don’t wait for someone else to solve it, we invest the resources into studying the science ourselves. When we get a particularly tough case, we don’t refer to an expert – we are the experts. And when a patient comes to us for help, we take that trust seriously. Doctors in our network are responsible for highly-cited, landmark studies that have literally changed the way fertility medicine is practiced. Preimplantation genetic screening, Single Embryo Transfer, egg freezing, safety of embryo biopsy, preimplantation genetic diagnosis, endometrial receptivity. These are just a few of the areas where we’ve dedicated the research time, money, and energy to establishing a better standard of care.
IVI-RMA Global has a single purpose: to provide hopeful patients from around the world with access to global leaders in the field of reproductive medicine, the safest and most innovative solutions, and a commitment to success that’s measured in months, not years.
CURRENT CLINICAL TRIALS
At IVI-RMA we don’t just say we’re on the cutting edge of our field, we are actually performing the clinical trials that are changing the way fertility patients are treated around the world. Whether it be investigating the human microbiome and its effect on IVF treatment or finding the ideal oxygen saturation for an embryo in culture, we are always looking for new ways to help make our practice safer, more effective, and better for you, our patients.
Evaluation of the Impact of Reduced Oxygen Concentration on Live Birth Rate
The embryo culture system is designed to recreate the environment in the female reproductive tract. Recent evidence suggests that lowering the oxygen concentration from 5% to 2% after day 3 of embryo development is actually closer to the conditions to which the embryo is exposed in a natural setting. This study is examining whether or not this “closer to nature” approach results in higher pregnancy rates in IVF patients. Principal Investigators: Scott J Morin, MD, Daniel J Kaser, MD
The Human Microbiome and IVF Outcomes
Evidence from multiple different disciplines in medicine and nutrition has revealed the important relationship between the bacteria naturally living on our bodies (also known as our microbiome) and our general health and wellbeing. Preliminary studies have indicated that abnormalities in the microbiome may influence fertility. This study is collecting specimens from fertility patients to determine whether microbiome testing might reveal patients who would benefit from treatments that restore a normal microbiome. Principal Investigators: Jason M Franasiak, MD
Screening of Low Responders for Aneuploidy to Improve Reproductive Efficiency (Solaire)
A landmark randomized controlled trial by RMA doctors established that preimplantation genetic screening improves outcomes over traditional embryo selection techniques. This new study is focused specifically on patients with diminished ovarian reserve or poor response to IVF stimulation to study PGS in these challenging patients. Principal Investigators: Richard T Scott, MD, HCLD
The goal of IVI-RMA Global is to lead the way in scientific research and technological advancements in reproductive medicine, with the ultimate aim of improving patient care. With a team of more than 70 investigators (clinicians, embryologists, biochemists and others) and more than 300 ongoing studies, our research team is devoted to the being on the cutting edge of assisted reproductive technology (ART).
Our physicians are constantly being recognized by the scientific community for their dedication to research in the field. Below are a few of the most recent and notable awards received by our physicians.
SRI Pfizer President’s Presenter Award - Scott Morin, MD (2018)
SRI Pfizer President’s Presenter Award for “Epigenetic clock model of somatic aging accurately predicts chronological age when applied to white blood cells but not cumulus cells in reproductive age women”, at the 65th annual meeting of the Society for Reproductive Investigation (SRI), held in San Diego, CA on March 6-10 2018
SRBT Clinical Science Award - Scott Morin, MD (2017)
SRBT Clinical Science Award for “The LO2 Trial, Phase I: A Paired Randomized Controlled Trial (RCT) Comparing Blastulation Rate in Ultra-Low (2%) VS. Low (5%) Oxygen in Extended Culture (EC)” at the 73rd annual meeting of the American Society of Reproductive Medicine (ASRM), held in San Antonio, TX, October 28-November 1, 2017.
Stanford Child Health Research Institute Grant Recipient - Jonathan Kort, MD (2017)
The Stanford Child Health Research Institute (CHRI) Grant and Postdoctoral Support program aims to develop and support innovative maternal and child health-focused clinical and translational research.